3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts